ARTAN Bio | BiotechTV

top of page

ASGCT 2026: Michael Torres isn't slowing down after selling his antibody-drug conjugate company to Eli Lilly. Here's his gene therapy play

He describes the work he is involved in with ARTAN Bio, which has a tRNA suppressors approach to diseases of aging and logevity. Plus, a unique crypto financing angle to this story. Coverage brought to you by

Company News

9 hours ago

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

Learn more

bottom of page

ASGCT 2026: Michael Torres isn't slowing down after selling his antibody-drug conjugate company to Eli Lilly. Here's his gene therapy play

Follow BiotechTV

Sponsors

Sponsor Spotlight